Low-molecular-weight sodium hyaluronate in the treatment of bacterial corneal ulcers

Graefes Arch Clin Exp Ophthalmol. 1992;230(1):20-3. doi: 10.1007/BF00166757.

Abstract

A double-blind clinical trial was performed on 26 patients suffering from corneal ulcers of proven (i.e., culture-positive) bacterial etiology. After their recruitment, the subjects were randomly assigned to one of the following treatment protocols: (1) tobramycin (15 mg/ml) in saline applied at 1 drop/h or (2) tobramycin (15 mg/ml) in low-molecular-weight hyaluronic acid applied at 1 drop/h. The sample size was adjusted according to a type I error of 0.01 and type a II error of 0.05 for a minimal expected difference of 35%. The healing time was calculated from the beginning of treatment to the day on which a follow-up fluorescein test proved to be negative. The mean healing time (+/- SD) was 3.5 +/- 0.9 days in the sodium hyaluronate group and 5.9 +/- 1.5 days in the saline group (P less than 0.001). These results suggest that treatment with an antibiotic dissolved in low-molecular-weight sodium hyaluronate can further shorten the clinical course of a bacterial corneal ulcer.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Corneal Ulcer / drug therapy*
  • Corneal Ulcer / microbiology
  • Double-Blind Method
  • Drug Carriers
  • Eye Infections, Bacterial / drug therapy*
  • Female
  • Follow-Up Studies
  • Humans
  • Hyaluronic Acid / therapeutic use*
  • Male
  • Middle Aged
  • Pseudomonas Infections / drug therapy
  • Staphylococcal Infections / drug therapy
  • Tobramycin / therapeutic use
  • Treatment Outcome

Substances

  • Drug Carriers
  • Hyaluronic Acid
  • Tobramycin